ArticleLeukemia2008
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
Article in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 111 citations in OpenAlex.
- Physiological MplW514L expression in hematopoietic stem cell causes an essential thrombocythemia and progressive myelofibrosis.The Journal of clinical investigation · 2026Article
- Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.Medical oncology (Northwood, London, England) · 2022Article
- MAEA is an E3 ubiquitin ligase promoting autophagy and maintenance of haematopoietic stem cells.Nature communications · 2021Article
- Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the RareCase reports in hematology · 2020Article
- Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.Cancer medicine · 2019Article
- Article
- Article
- Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.American journal of hematology · 2019Article
- Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.Scientific reports · 2017Article
- Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.The American journal of pathology · 2017Article
- Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.Frontiers in endocrinology · 2017Review
- Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.JAK-STAT · 2016Article
- [Advances in research of essential thrombocythemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Review
- The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control.Cellular and molecular life sciences : CMLS · 2015Review
- Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.Translational pediatrics · 2015Review
- Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.Iranian journal of pediatric hematology and oncology · 2015Article
- Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.Mediators of inflammation · 2015Review
- Molecular genetics of myelofibrosis and its associated disease phenotypes.Translational medicine @ UniSa · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5-10% of primitive myelofibrosis (PMF) cases as decisive oncogenic events capable of triggering the disease. Here we report additional mutations located in exon 10 of MPL in PMF patients. We investigated whether these new mutations also lead to cell transformation. MPL exon 10 was systematically sequenced in 100 PMF patients. Seven different mutations were found in eight patients. We introduced each MPL mutant in Ba/F3 cells to determine whether they correspond to gain-of-function mutations. Only MPL W515 mutations induced (1) Ba/F3 proliferation independently of growth factors, (2) tumorigenesis in nude mice, (3) spontaneous activation of JAK/STAT, RAS/MAPK and PI3K transduction pathways and (4) increased S phase of cell cycle. Similar to all other myeloproliferative disorder oncogenic events identified to date, these results demonstrate that only the detected MPL W515 mutations trigger spontaneous MPL activation leading to a G(1)/S transition activation. The other mutations are devoid of significant transforming activity but may synergize with JAK2 V617F or other not yet characterized molecular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.